MCA (mucinous-like cancer antigen) can be measured in the biological fluids of patients by means of a solid phase enzyme immunoassay. This study describes the results of MCA determination in sera of 230 patients with benign (99) and malignant (131) breast diseases. MCA levels were significantly higher in breast cancer patients than in non cancer patients and in healthy subjects (p < 0.001). MCA concentrations tended to increase as the stage of the disease advanced. The 95th percentile of MCA value distribution in normal subjects showed a diagnostic sensitivity in breast cancer patients of 16.3% at stage I,26.2% at stages II-III and 52% at stage IV. In a group of 118 cancer patients, MCA and CEA were tested simultaneously. The diagnostic sensitivity and specificity of MCA and CEA assays was very similar; nevertheless the association of the two tests showed 11 cases with high levels of MCA and low levels of CEA and 9 patients with high levels of CEA and low levels of MCA. Seventy-four out of 118 patients were negative for both markers and in 22 out of 118 patients markers were positive. The new marker MCA appeared to correlate with breast cancer and gave different information complementary to CEA.
MagnaniJ.L., SteplewskiZ., KoprowskiH., GinsburgV.Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin.Cancer Res1983; 43: 5489–92.
3.
WrightGLJr.Application of monoclonal antibodies to the study of human cancer. In: GL Wright, ed. Monoclonal antibodies and cancer.New York, Basel: Marcel Dekker Inc.1984; 23: 1.
4.
RossA.H., MitchellR.F., SteplewskiZ., KoprowskiH.Identification and isolation of melanoma associated antigens with monoclonal antibodies.Hybridoma1982; 1: 413.
5.
JalankoH., KuuselaP., RobertsP., SipponenP., HaglundC.A.J., MakelaO.Comparison of new tumor marker CA 19-9 with fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases.J Clin Pathol1984; 37: 218–22.
6.
HockeyM.S., StokesH.J., ThompsonH.Carcinoembryonic antigen (CEA) expression and heterogeneity in primary and autologous metastatic gastric tumors demonstrated by a monoclonal antibody.Br J Cancer1984; 49: 129–33.
7.
ColcherD., Horan-HandP., NutiM., SchlomJ.A spectrum of monoclonal antibodies reactive with human mammary tumor cells.Proc Natl Acad Sci1981; 78: 3199–203.
8.
YuanD., HandlerF.J., VitettaE.S.Characterisation of a monoclonal antibody reactive with a subset of human breast tumors.J Natl Cancer Inst1982; 68: 719–28.
9.
KufeD.W., NadlerL., SargentL.Biological behaviour of human breast carcinoma associated antigens expressed during cellular proliferation.Cancer Res1983; 43: 851–7.
10.
NutiM., TeramotoY.A., Marianni-CostantiniR., Horan-HandP., ColcherD., ScholmJ.A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations.Int J Cancer1982; 29: 539–45.
11.
SouleH.R., LinderE., EdgingtonT.S.Membrane 126-kilodalton phosphoglycoprotein associated with human carcinomas identified by a hybridoma antibody to mammary carcinoma cells.Proc Natl Acad Sci USA1983; 80: 1332–36.
12.
WhiteC.A., DulbeccoR., AllenR., BowmanM., ArmstrongB.Two monoclonal antibodies selective for human mammary carcinoma.Cancer Res1985; 45: 1337–43.
13.
PapsideroL.D., CroghanG.A., O'ConnellM.J., Valen-zuelaL.A., NemotoT., ChuT.M.Monoclonal antibodies (F36/22 and M7/105) to human breast carcinoma.Cancer Res1983; 43: 1741–47.
14.
MenardS., TagliabueE., CanevariS., FossatiG., ColnaghiM.I.Generation of monoclonal antibodies reacting with normal and cancer cells of human breast.Cancer Res1983; 43: 1741–7.
15.
Manan-CostantiniR., ColnaghiM.I., LeoniF., MenardS., CerasolS., RilkeF.Immunohistochemical reactivity of a monoclonal antibody prepared against human breast carcinoma.Virchows Arch Pathol Anat1984; 402: 389–404.
16.
BurchellJ., WangD., Taylor-PapadimitriouJ.Detection of the tumor-associated antigens recognized by the monoclonal antibodies HMGF-1 and 2 in serum from patients with breast cancer.Int J Cancer1984; 34: 763–8.
17.
ArklieJ., Taylor-PapadimitriouJ., BodnerW., EganM., MillsR.Differentiation antigens expressed by epithelial cells in the lactating breast are also detectable in breast cancers.Int J Cancer1981; 28: 23–9.
18.
Taylor-PapadimitrouJ., PetersonJ.A., ArklieJ., BurchellJ., CerianiR.L., BodmerW.F.Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture.Int J Cancer1981; 28: 17–21.
19.
CerianiR.L., PetersonJ.A., LeeJ.Y., MoncadaR., BlankE.W.Characterization of cell surface antigens of human mammary epithelial cells with monoclonal antibodies prepared against human milk fat globule.Somatic Cell Genet1983; 9: 415–27.
20.
CerianiR.L., OrthendhalD., SasakiM.Use of human mammary epithelial antigens (HME-Ags) in breast cancer diagnosis.Cancer Detect Prevent1981; 4: 603–9.
21.
CerianiR.L., ThompsonK., PetersonJ.A., AbrahamsS.Surface differentiation antigens of human mammary epithelial cells carried on the human milk fat globule.Proc Natl Acad Sci Usa1977; 74: 582–6.
22.
StahliC., StaehelinT., MiggianoV., ScmidtJ., HaringP.High frequencies of antigen-specific hybridomas: de-pendence on immunization parameters and prediction by spleen cell analysis.J Immunol Methods1980; 32: 297–304.
23.
StahliC., StaehelinT., MiggianoV.Spleen cells analysis and optimal immunization for high-frequency production of specific hybridomas.Methods in Enzy-mology1983; 92: 26–36.
24.
StahliC., TakacsB., MiggianoV., CarmannH.mAb against breast cancer antigens.Experientia1985; 41: 1377–81.
25.
ZenklusenH.R., von OverbeckJ., StahliC., GudatF., RolinkH., HeitzP.U.The immunohistochemical reactivity of a monoclonal antibody (MAb b-12) against breast carcinomas and other normal and neoplastic human tissues.Virchows Archives1988, 413: 3–10.
26.
StahliC., CaravattiM., TakacsB., AndresR., CarmanH.A mucinous carcinoma associated antigen (MCA) defined by three MAB against different epitopes.Cancer Res1988; 48: 6799–802.
27.
UICC.TNM classification of malignant tumors.Geneva: MH Harmer, 1979.
28.
HortonJ.Follow-up of breast cancer patients.Cancer1984; 53: 790.
29.
LokichJ.J., ZamcheckN., LowensteinM.Sequential carcinoembryonic antigen levels in therapy of metastatic breast cancer: a predictor and monitor of response and relapse.Ann Intern Med1978; 89: 902.
30.
WangD.Y., KnybaR.E., BulbrookR.D., MillisR.R., HaywardJ.L.Serum carcinembryonic antigen in the diagnosis and prognosis of women with breast cancer.Eur J Clin Oncol1984; 20: 25.
31.
LuthgensM., SchlegelG.CEA-TPA in der klinischen Tumordiagnostik, insbesondere des mamma-kar-zinoms. In: Bonadonna G, ed. Tumor Breast Cancer Diagnosis and Management.Chichester New York: John Wile & sons Ltd,1984; 1: 109.
32.
KjellgrenK.The prognostic significance of consecutive determinations of serum tissue polypeptide antigen (TPA) in human breast cancer. In: Lerhmann FG, ed. Carcinoembryonic Proteins.North Holland: Elsevier,1979; 11: 607.
33.
NemotoT., ConstantineR., ChuT.M.Human tissue polypeptide antigen in breast cancer.J Natl Cancer Inst1979; 63: 1347.
34.
BombardieriE., Biomarcatori. In: BonadonnaG., ed. Manuale di Oncologia Medica.Milano: Masson Italia Editori, Milano1987; 147.
35.
KufeD., InghiramiG., AbeM., HayesP., Justi-WheelerH., ScholmJ.Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast cancer.Hybridoma1984; 3: 223.
36.
TobiasR., RothwellC., WagnerJ., GreenA., LiuY.S.K.Development and evaluation of a radioimmunoassay for the detection of a monoclonal antibody defined breast tumor associated antigen 115D8/DF3. Proceedings of Symposium of American Association for Analytical Clinical Chemistry. Atlanta, July 1985; 24.
37.
GionM., MioneR., DittadiR., FasanS., PalliniA., BuscagninG.Evaluation of CA 15.3 serum levels in breast cancer patients.J Nucl Med All Sci1986; 30: 1.
38.
ColomerR., RuibalA., NavarroM., EncaboG., SoleL.A., SalvadorL.Circulating CA 15.3 levels in breast cancer. Our present experience.Int J Biol Markers1986; 1: 89–92.
39.
Pons-AnicetD.M.F., KrebsB.P., MiraR., NamerM.Value of CA 15-3 in the follow-up of breast cancer patients.Br J Cancer1987; 55: 567–9.
40.
HilkensJ., KroezenV., BonfrerJ.M.G., BruninP.F., Hil-ghersJ., Van EijkerenM.A sandwich radioimmunoassay for a new antigen (MAM-6) present in the sera of patients with metastatized carcinomas. In: PeetersH., ed. Protides of the biological fluids.Oxford, New York: Pergamon Press, 1984; 651.
41.
MartinazziM., CrivelliF., GrassiC., ZampattiC.Immunohistochemical distribution of mucinous-like carcinoma associated antigen (MCA) in breast and non-breast cancer in comparison with other biological parameters.Int J Biol Markers1990; 5: 138–44.
42.
BieglmayerC., SzepesiT., NeunteufelW., NowotnyMCA: A monoclonal antibody defined breast tumor associated antigen and its relation to CA 15-3.Tumor Biology1989; 10: 232–42.
43.
BombardieriE., GionM., MioneR., DittadiR., BruscagninM., BuraggiG.A mucinous-like carcinoma-associated antigen (MCA) in the tissue and blood of patients with primary breast cancer.Cancer1989; 3: 490–5.
44.
Saccani JottiG., GrassiE., SeregniE.I marcatori serici ed istochimici nella patologia mammaria: dati preliminari.Quaderni Ligand Quarterly1985; 4: 141.
45.
BuckmanR., CoombesR.C., DearnaleyD.P., GoreM., GustersonB., NevilleA.M.Some clinical uses of biological markers. In: Bonadonna G, ed. Breast Cancer Diagnosis and management.Chichester, New York: John Wile and Sons, Ltd.1984; 1: 109.
46.
BatesS.E., LongoD.L.Tumor markers: value and limitations in the management of cancer patients.Cancer Treat Rev1985; 12: 163.
47.
HaagensenD.E., KistersS.J., VandervoordeJ.P.Evaluation of carcinoembryonic antigen as a plasma monitor for human breast carcinoma.Cancer1978; 42: 1512.
